Article

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial

2025-12-15

Abstract excerpt

Metastatic pancreatic ductal adenocarcinoma (PDAC) remains deadly, with minimal improvement in prognosis over the past 20 years despite expansion of our chemotherapeutic arsenal. The complex tumor microenvironment (TME) of PDAC in the advanced stage, which often accompany clinical diagnosis, likely contributes to the limited efficacy of current standard of care chemotherapy. Informed by mechanistic preclinical stu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fa9f9fce-0dab-5e1d-860b-d27b9fd17847
DOI: 10.64898/2025.12.14.25342225

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trialDOI 10.64898/2025.12.14.25342225Read

Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic CancerSemantic proximity Read

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read

Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospectsSemantic proximity Read

Assessment of the stromal contribution to Sonic Hedgehog‐dependent pancreatic adenocarcinomaSemantic proximity Read

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC ModelSemantic proximity Read

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity Read

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancerSemantic proximity Read

Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity Read

Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer.Semantic proximity Read

Hedgehog Signaling: Networking to Nurture a Promalignant Tumor MicroenvironmentSemantic proximity Read